Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-05-21
2008-11-25
Foley, Shanon A. (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S142100, C424S150100, C436S512000, C436S513000
Reexamination Certificate
active
07456264
ABSTRACT:
Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
REFERENCES:
patent: 4689299 (1987-08-01), Insel et al.
patent: 2002/0082386 (2002-06-01), Mangold et al.
patent: 2004/0076638 (2004-04-01), Shiloach et al.
patent: WO 99/47929 (1999-09-01), None
patent: WO 02/46208 (2002-06-01), None
patent: WO-03/040384 (2003-05-01), None
Greenspan et al. (Nature Biotechnology 17: 936-937, 1999).
Abbas et al. (Cell. Mol. Immunol. 3rd ed., 1997, p. 45).
Roitt et al. (Immunol. 3rd ed., 1993, p. 4.8).
Little, Stephen F. et al., “Characterization of lethal factor binding and cell receptor binding domains of protective antigen ofBacillus anthracisusing monoclonal antibodies,”Microbiology, vol. 142:707-715 (1996).
Little, S.F. et al., “Passive Protection by Polyclonal Antibodies againstBacillus anthracisInfection in Guinea Pigs,”Infection and Immunity, vol. 65(12):5171-5175 (1997).
Morrow, Phillip R. et al., “Anthrax Vaccination: A Source for a Panel of Potent Fully Human Monoclonal Antibodies using Xenerex Technology,”National Symposium on Basic Aspects of Vaccines, May 14-15, 2003.
Rudikoff, Stuart et al., “Single Amino acid substitution altering antigen-binding specificity,”Proc. Natl. Acad. Sci. USA, vol. 79:1979-1983 (1982).
European Search Report for Application No. 04809410.6-2406, dated Jan. 16, 2007.
Little, S.F. et al., “Production and Characterization of Monoclonal Antibodies Against the Lethal Factor Component ofBacillus anthracisLethal Toxin.”Infection and Immunity, Jun. 1990, vol. 58, No. 6, pp. 1606-1613.
Cirino, N.M. et al., “Disruption of Anthrax Toxin Binding with the Use of Human Antibodies and Competitive Inhibitors.”Infection and Immunity, Jun. 1999, vol. 67, No. 6, pp 2957-2963.
Maynard, J.A. et al., “Protection Against Anthrax Toxin by Recombinant Antibody Fragments Correlates with Antigen Affinity.”Nature Biotechnology, Jun. 2002, vol. 20, pp. 597-601.
Mourez, M. et al., “Designing a Polyvalent Inhibitor of Anthrax Toxin.”Nature Biotechnology, Oct. 2001, vol. 19, pp. 958-961.
International Search Report to PCT/US04/16213, dated Mar. 24, 2005.
Written Opinion of the International Searching Authority to PCT/US04/16213, dated Mar. 24, 2005.
International Preliminary Examination Report to PCT/US04/16213, dated Dec. 16, 2005.
Blanset Diann
Keler Tibor
Lowy Israel
Srinivasan Mohan
Vitale Laura A.
Foley Shanon A.
Gangle Brian J
Lahive & Cockfield LLP
Medarex Inc.
Remillard, Esq. Jane E.
LandOfFree
Human monoclonal antibodies against Bacillus anthracis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibodies against Bacillus anthracis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies against Bacillus anthracis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4030515